Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure

C M Chu, V L Chan, A W N Lin, I W Y Wong, W S Leung, C K W Lai, C M Chu, V L Chan, A W N Lin, I W Y Wong, W S Leung, C K W Lai

Abstract

Background: Non-invasive ventilation (NIV) has been shown to reduce intubation and in-hospital mortality in patients with chronic obstructive pulmonary disease (COPD) and acute hypercapnic respiratory failure (AHRF). However, little information exists on the outcomes following discharge. A study was undertaken to examine the rates of readmission, recurrent AHRF, and death following discharge and the risk factors associated with them.

Methods: A cohort of COPD patients with AHRF who survived after treatment with NIV in a respiratory high dependency unit was prospectively followed from July 2001 to October 2002. The times to readmission, first recurrent AHRF, and death were recorded and analysed against potential risk factors collected during the index admission.

Results: One hundred and ten patients (87 men) of mean (SD) age 73.2 (7.6) years survived AHRF after NIV during the study period. One year after discharge 79.9% had been readmitted, 63.3% had another life threatening event, and 49.1% had died. Survivors spent a median of 12% of the subsequent year in hospital. The number of days in hospital in the previous year (p = 0.016) and a low Katz score (p = 0.018) predicted early readmission; home oxygen use (p = 0.002), APACHE II score (p = 0.006), and a lower body mass index (p = 0.041) predicted early recurrent AHRF or death; the MRC dyspnoea score (p<0.001) predicted early death.

Conclusions: COPD patients with AHRF who survive following treatment with NIV have a high risk of readmission and life threatening events. Further studies are urgently needed to devise strategies to reduce readmission and life threatening events in this group of patients.

References

    1. Intensive Care Med. 2003 Mar;29(3):419-25
    1. Am Rev Respir Dis. 1991 Dec;144(6):1234-9
    1. Thorax. 2003 Oct;58(10):867-71
    1. Crit Care Med. 2004 Feb;32(2):372-7
    1. N Engl J Med. 2004 Mar 4;350(10):1005-12
    1. Med Care. 1976 May;14(5 Suppl):116-8
    1. Eur Respir J. 2000 Jan;15(1):98-104
    1. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):807-13
    1. Lancet. 2000 Jun 3;355(9219):1931-5
    1. Am J Respir Crit Care Med. 2001 Feb;163(2):540-77
    1. Chest. 2001 Jun;119(6):1840-9
    1. Thorax. 2001 Sep;56(9):708-12
    1. Thorax. 2002 Jan;57(1):29-33
    1. Thorax. 2002 Feb;57(2):137-41
    1. Crit Care Med. 2002 Jul;30(7):1610-5
    1. Eur Respir J. 2002 Sep;20(3):529-38
    1. Thorax. 2003 Feb;58(2):100-5
    1. Eur Respir J. 2003 Feb;21(2):202-3
    1. Crit Care Med. 1985 Oct;13(10):818-29
    1. J Chronic Dis. 1987;40(5):373-83
    1. Chest. 1987 Dec;92(6):971-8
    1. Chest. 1992 Sep;102(3):912-7
    1. Lancet. 1993 Jun 19;341(8860):1555-7
    1. Chest. 1993 Oct;104(4):1222-9
    1. Am J Crit Care. 1994 Jan;3(1):6-10
    1. Crit Care Med. 1994 Oct;22(10):1584-90
    1. Eur Respir J. 1994 Sep;7(9):1645-52
    1. Am J Respir Crit Care Med. 1995 Jun;151(6):1799-806
    1. Am J Respir Crit Care Med. 1995 Aug;152(2):538-44
    1. N Engl J Med. 1995 Sep 28;333(13):817-22
    1. JAMA. 1995 Dec 20;274(23):1852-7
    1. Mayo Clin Proc. 1996 Jun;71(6):533-42
    1. Eur Respir J. 1996 Mar;9(3):422-30
    1. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):353-8
    1. Intensive Care Med. 1996 Feb;22(2):94-100
    1. Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):959-67
    1. Thorax. 1996 Oct;51(10):1048-50
    1. Crit Care Med. 1998 Jan;26(1):71-8
    1. Thorax. 1998 Jun;53(6):495-8
    1. Chest. 1998 Dec;114(6):1636-42
    1. Chest. 2003 Aug;124(2):459-67

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe